441 related articles for article (PubMed ID: 22168282)
1. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.
Bugelski PJ; Martin PL
Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282
[TBL] [Abstract][Full Text] [Related]
2. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.
Martin PL; Bugelski PJ
Br J Pharmacol; 2012 Jun; 166(3):806-22. PubMed ID: 22168335
[TBL] [Abstract][Full Text] [Related]
3. The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients.
Polson AG; Fuji RN
Br J Pharmacol; 2012 Jul; 166(5):1600-2. PubMed ID: 22364106
[TBL] [Abstract][Full Text] [Related]
4. Marketed therapeutic antibodies compendium.
Reichert JM
MAbs; 2012; 4(3):413-5. PubMed ID: 22531442
[TBL] [Abstract][Full Text] [Related]
5. [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].
Guhl G; Díaz-Ley B; Fernández-Herrera J
Actas Dermosifiliogr; 2008; 99(1):5-33. PubMed ID: 18206084
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Tutrone WD
Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
[TBL] [Abstract][Full Text] [Related]
7. Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.
Kyriakidis I; Tragiannidis A; Zündorf I; Groll AH
Mycoses; 2017 Aug; 60(8):493-507. PubMed ID: 28444889
[TBL] [Abstract][Full Text] [Related]
8. The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.
Lansita JA; Mounho-Zamora B
Curr Pain Headache Rep; 2015; 19(2):2. PubMed ID: 25681157
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
Ternant D; Paintaud G
Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
[TBL] [Abstract][Full Text] [Related]
10. [Anti IL-2 receptor antibody--basiliximab].
Nakagawa Y; Saitou K; Takahashi K
Nihon Rinsho; 2005 May; 63 Suppl 5():713-7. PubMed ID: 15954434
[No Abstract] [Full Text] [Related]
11. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Bioconjug Chem; 2013 Jan; 24(1):97-104. PubMed ID: 23249376
[TBL] [Abstract][Full Text] [Related]
12. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
13. Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies.
Yu J; Kalaria DR; Kalia YN
J Control Release; 2011 Nov; 156(1):53-9. PubMed ID: 21803083
[TBL] [Abstract][Full Text] [Related]
14. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
15. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method.
Oitate M; Nakayama S; Ito T; Kurihara A; Okudaira N; Izumi T
Drug Metab Pharmacokinet; 2012; 27(3):354-9. PubMed ID: 22146109
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody treatments for multiple sclerosis.
Rose JW; Foley J; Carlson N
Curr Neurol Neurosci Rep; 2008 Sep; 8(5):419-26. PubMed ID: 18713579
[TBL] [Abstract][Full Text] [Related]
17. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
van Meer PJ; Kooijman M; Brinks V; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
MAbs; 2013; 5(5):810-6. PubMed ID: 23924803
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology and therapeutic applications of monoclonal antibodies.
Castelli MS; McGonigle P; Hornby PJ
Pharmacol Res Perspect; 2019 Dec; 7(6):e00535. PubMed ID: 31859459
[TBL] [Abstract][Full Text] [Related]
20. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
